intrathecaم Ketamine, Morphine and Both for Lower Abdominal Cancer Surgery Pain

Effects of Intrathecally Administered Ketamine, Morphine and Their Combination in Patients Undergoing Major Abdominal Cancer Surgery

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02726828

Enrollment

Registered

2016-04-04

Start date

2015-10-31

Completion date

2016-04-30

Last updated

2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

this study investigates the analgesic efficacy and other possible effects of ketamine, morphine, and both together when administered intrathecally for control of postoperative pain following lower abdominal cancer surgeries.

Interventions

DRUGintrathecal morphine

patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.

DRUGintrathecal ketamine

patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.

DRUGintrathecal morphine + ketamine

patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesia (ASA) I-III patients. * aged 30-50 years. * scheduled for major abdominal cancer surgery.

Exclusion criteria

* Patients with a known allergy to the study drugs. * significant cardiac, respiratory, renal or hepatic disease. * coagulation disorders. * infection at or near the site of intrathecal injection. * drug or alcohol abuse. * BMI \> 30 kg/m2. * psychiatric illnesses that may interfere with perception and assessment of pain.

Design outcomes

Primary

Measure	Time frame	Description
Visual Analogue Scale (VAS) scores	24 hours postoperative	postoperative pain measured by this score.
time to first analgesic request	24 hours postoperative	the time passed till the first request of rescue analgesia by the patients
total analgesic consumption	24 hours postoperative	the total amount of rescue analgesic drug used allover follow up period

Secondary

Measure	Time frame	Description
side effects	24 hours postoperative	the type and rate of incidence of side effects during the follow up period

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026